Alendomax is used to treat osteoporosis in women and Paget disease of bone in both men and women.
Alendomax works on bone tissue by binding to hydroxyapatite, which is part of the mineral matrix of bone and plays an important role in the mevalonate pathway.
This inhibition prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) in osteoclasts, which are essential for many processes such as post-polyploidization and granylgeranyltransferase of small GTPase signaling auxiliary proteins.
This activity leads to inhibition of the activity of cells that break down bone, which reduces bone resorption and turnover. In postmenopausal women, alendronate contributes to reducing the generally high rate of bone turnover.